GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (FRA:8STN) » Definitions » Cyclically Adjusted Book per Share

Sorrento Therapeutics (FRA:8STN) Cyclically Adjusted Book per Share : €0.00 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Sorrento Therapeutics Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Sorrento Therapeutics's adjusted book value per share for the three months ended in Jun. 2023 was €-0.404. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Jun. 2023.

During the past 12 months, Sorrento Therapeutics's average Cyclically Adjusted Book Growth Rate was -1.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Sorrento Therapeutics was 21.50% per year. The lowest was 4.30% per year. And the median was 5.90% per year.

As of today (2024-05-14), Sorrento Therapeutics's current stock price is €0.298. Sorrento Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €0.00. Sorrento Therapeutics's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sorrento Therapeutics was 91.23. The lowest was 0.01. And the median was 2.50.


Sorrento Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Sorrento Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Cyclically Adjusted Book per Share Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.24 1.40 1.33 1.61 -

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 2.06 - - -

Competitive Comparison of Sorrento Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Sorrento Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sorrento Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sorrento Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book= Book Value per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.404/128.7287*128.7287
=-0.404

Current CPI (Jun. 2023) = 128.7287.

Sorrento Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201309 1.402 98.790 1.827
201312 2.118 98.326 2.773
201403 1.855 99.695 2.395
201406 2.013 100.560 2.577
201409 1.931 100.428 2.475
201412 2.437 99.070 3.167
201503 2.548 99.621 3.292
201506 2.234 100.684 2.856
201509 3.449 100.392 4.423
201512 3.528 99.792 4.551
201603 2.218 100.470 2.842
201606 1.934 101.688 2.448
201609 1.233 101.861 1.558
201612 1.491 101.863 1.884
201703 1.062 102.862 1.329
201706 1.075 103.349 1.339
201709 1.400 104.136 1.731
201712 2.034 104.011 2.517
201803 2.092 105.290 2.558
201806 1.873 106.317 2.268
201809 1.598 106.507 1.931
201812 1.506 105.998 1.829
201903 0.955 107.251 1.146
201906 0.603 108.070 0.718
201909 0.318 108.329 0.378
201912 0.422 108.420 0.501
202003 0.447 108.902 0.528
202006 0.526 108.767 0.623
202009 0.666 109.815 0.781
202012 0.493 109.897 0.577
202103 0.681 111.754 0.784
202106 0.519 114.631 0.583
202109 0.368 115.734 0.409
202112 0.222 117.630 0.243
202203 0.548 121.301 0.582
202206 0.286 125.017 0.294
202209 0.284 125.227 0.292
202212 -0.038 125.222 -0.039
202303 -0.250 127.348 -0.253
202306 -0.404 128.729 -0.404

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Sorrento Therapeutics  (FRA:8STN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sorrento Therapeutics was 91.23. The lowest was 0.01. And the median was 2.50.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Sorrento Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (FRA:8STN) Business Description

Industry
Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (FRA:8STN) Headlines

No Headlines